A PHASE 2/3, MULTICENTER, RANDOMIZED STUDY OF RALUDOTATUG DERUXTECAN (RDXD), A CDH6-DIRECTED ANTIBODY-DRUG CONJUGATE, IN SUBJECTS WITH PLATINUMRESISTANT, HIGH-GRADE OVARIAN, PRIMARY PERITONEAL, OR FALLOPIAN TUBE CANCER
- Registry ID
- DS6000-109
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- DAIICHI SANKYO INC
- Start date
- 2025-06-26
- Last update
- 2024-01-04
Conditions
- OVARIAN CANCER PRIMARY PERITONEAL
Related clinical trials
- MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF CARBOPLATIN PLUS MIRVETUXIMAB SORAVTANSINE FOLLOWED BY MIRVETUXIMAB SORAVTANSINE CONTINUATION IN FOLATE RECEPTOR-ALPHA POSITIVE, RECURRENT PLATINUM-SENSITIVE, HIGH-GRADE EPITHELIAL OVARIAN, PRIMARY PERITONEAL OR FALLOPIAN TUBE CANCERS FOLLOWING 1 PRIOR LINE OF PLATINUM-BASED CHEMOTHERAPY
- A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NIRAPARIB IN PATIENTS WITH ADVANCED, RELAPSED, HIGH-GRADE SEROUS EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO HAVE RECEIVED THREE OR FOUR PREVIOUS CHEMOTHERAPY REGIMENS
- "A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL OF PEGYLATE LIPOSOMAL DOXORUBIN (PLD) PLUS AMG 386 OR PLACEBO IN WOMEN IN RECURRENT PARTIALLY PLATINUM SENSITIVE OR RESISTANT EPITHELIAL OVARIAN, PRIMARY PERITONEAL, OR FALLOPIAN TUBE CANCER,"
View on source registry